

What Is Claimed Is:

1. A compound composed of 11-24 amino acid residues
- 5 comprising the amino acid sequence:

$A_1 - A_2 - A_3 - C_4 - C_5 - C_6 - A_7 - C_8 - A_9 - A_{10} - A_{11} - A_{12} - C_{13} - A_{14} - C_{15} - C_{16} - C_{17} - A_{18}$

or a pharmaceutically acceptable salt or an N-terminal

- 10 acylated or C-terminal amidated or esterified form thereof, said compound being either in a linear or in a disulfide-bridged form, wherein:

each of $A_1 - A_3$ is independently present or not present, and if present each is independently a basic, hydrophobic,
15 polar/large, or small amino acid;

each of C_4 and C_{17} is independently present or not present, and if present each is independently selected from the group consisting of cysteine, homocysteine, penicillamine, a basic amino acid, a hydrophobic amino acid,
20 a polar/large amino acid and a small amino acid;

C_5 is selected from the group consisting of cysteine, homocysteine, penicillamine, a basic amino acid, a hydrophobic amino acid, a polar/large amino acid and a small amino acid;

- 25 each of C_6 , C_8 , C_{13} and C_{15} is independently selected from the group consisting of cysteine, homocysteine, penicillamine, a basic amino acid, a hydrophobic amino acid, a polar/large amino acid, a small amino acid and an acidic amino acid;

C₁₆ is selected from the group consisting of cysteine, homocysteine, penicillamine, a hydrophobic amino acid or a small amino acid;

each of A₇ and A₁₄ is independently a hydrophobic or a 5 small amino acid;

A₉-A₁₂ taken together are capable of effecting a β -turn when contained in the compound and at least one of A₉-A₁₂ is a basic amino acid;

A₁₈ is present or not present, and if present, is a 10 basic, hydrophobic, polar/large, or small amino acid;

at least about 15% to about 50% of the amino acid residues composing said compound are basic amino acids; and said compound has a net positive charge of at least +1 at physiological pH;

15 with the provisos that: (i) when one of C₄, C₅ or C₆ is cysteine, homocysteine or penicillamine, the other two are other than cysteine, homocysteine and penicillamine;

(ii) when one of C₁₅, C₁₆ or C₁₇ is cysteine, homocysteine or penicillamine, the other two are other than cysteine,

20 homocysteine and penicillamine;

and (iii) at least one of C₄, C₅, C₁₆ or C₁₇ is cysteine, homocysteine or penicillamine.

2. The compound of claim 1 which comprises two

25 disulfide bridges.

3. The compound of Claim 2, wherein one of said disulfide bridges links C₅-C₁₆ and the other links C₈-C₁₃.

4. The compound of Claim 3 which is selected from the group consisting of:

5 R-G-G-R-C-L-Y-C-R
 | | R
 | | R
 R-G-C-V-V-C-F (SEQ ID NO:104) ;

10 R-G-G-R-C-L-Y-C-R
 | | R
 | | R
 G-C-V-I-C-F (SEQ ID NO:105) ;

15 R-G-G-G-C-L-Y-C-R
 | | R
 | | R
 R-G-C-V-V-C-F (SEQ ID NO:106) ;

20 R-G-G-R-C-L-Y-C-R
 | | G
 | | W
 R-G-C-V-F-C-I (SEQ ID NO:107) ;

25 R-G-G-R-C-L-Y-C-R
 | | P
 | | R
 R-G-C-V-V-C-F (SEQ ID NO:108) ;

30 R-G-G-R-C-V-Y-C-R
 | | R
 | | R
 G-C-V-V-C-F (SEQ ID NO:109) ;

 K-G-G-R-C-L-Y-C-R
 | | R
 | | R
 G-C-V-V-C-F (SEQ ID NO:110) ;

 R-G-G-X-C-L-Y-C-R
 | | R
 | | R
 C-V-V-C-F (SEQ ID NO:111) ;

R-G-G-X-C-L-Y-C-X
| | R
| | R
R-G-C-V-V-C-F

(SEQ ID NO:112);

5 R-G-G-R-C-V-Y-C-R
| | X
| | R
R-G-C-V-V-C-F

(SEQ ID NO:113);

R-G-G-R-C-L-Y-C-R
| | K
| | K
10 R-G-C-V-V-C-W

(SEQ ID NO:114);

R-G-G-R-C-L-Y-C-R
| | X
| | R
R-G-C-V-V-C-Y

(SEQ ID NO:115);

15 R-G-S-G-C-L-Y-C-R
| | R
| | K
R-G-C-V-V-C-W

(SEQ ID NO:116);

R-A-T-R-C-I-F-C-R
| | R
| | R
20 R-G-C-V-V-C-F

(SEQ ID NO:117);

R-G-G-K-C-V-Y-C-R
| | X
| | R
R-G-C-V-V-C-F

(SEQ ID NO:118);

25 R-A-T-R-C-I-F-C-r
| | R
| | R
r-G-C-V-V-C-F

(SEQ ID NO:119);

R-G-G-K-C-V-Y-C-R
| | X
| | R
30 R-G-C-V-V-C-F

(SEQ ID NO:120);

r-g-g-r-c-l-y-c-r
| | r
| | r
r-g-c-v-v-c-f . . . (SEQ_ID_NO:121);

5 r-g-g-r-c-l-y-c-r
| | r
| | r
c-v-i-c-f (SEQ_ID_NO:122);

r-g-g-g-c-l-y-c-r
| | r
| r
10 r-g-c-v-v-c-f (SEQ_ID_NO:123);

r-g-g-r-c-l-y-c-r
| | g
| w
r-q-c-v-f-c-i (SEQ ID NO:124);

15 and the C-terminal amidated forms thereof, wherein X is
Har, x is D-Har, lower case letters represent D-amino acids
and lines between C or c residues represent disulfide
linkages.

20 5. The compound of Claim 2, wherein one of said disulfide bridges links C_5-C_8 and the other links $C_{13}-C_{16}$.

6. The compound of Claim 5 which is selected from the group consisting of:

25

RGGRCLYCRRRFCVVCGR (SEQ ID NO:125);

30 RGGRCLYCRRRFCIVCG (SEQ ID NO:126);

RGGGCLYCRRRF¹CVVCGR²

(SEQ ID NO:127);

5 RGGRCLYCRGWICFVCGR

(SEQ ID NO:128);

RGGRCLYCRPRFCVVCGR

(SEQ ID NO:129);

10 RGGRCVYCVRRRCVWCG

(SEQ ID NO:130);

KCCBCL YCBRRECWCC

(SEQ ID NO:131);

15 

(SEQ ID NO:132);

ПОСУДА УСКОРЕННАЯ

(SEQ ID NO:133);

20 
RGGRCVYCRXRECVVCGR

(SEO ID NO:134):

-PGGRGLYGRKKWCVAVGGR-

—(SEO-ID-NO.:135);

□ □
BCCBCLYCBYKBYKLYCBLYCCB

(SEQ ID NO:136);

30 RGSGCLYCRRKWCVVCGR

(SEQ ID NO:137):

100
RATRCIFCRRR¹FCVV²CGR

(SEQ ID NO:138);

5
RGGKCVYCRX¹RFCVV²CGR

(SEQ ID NO:139);

10
RATRCIFCrRR¹FCVV²CGr

(SEQ ID NO:140);

100
RGGKCVYCRxRFCVV²CGR

(SEQ ID NO:141);

15
rggrclys¹crrrfcVV²cgr

(SEQ ID NO:142);

rggrclys¹crrrfcivcg

(SEQ ID NO:143);

rgggclys¹crrrfcVV²cgr

(SEQ ID NO:144);

20
RGGRC¹LYCRGWIC²FVCGR

(SEQ ID NO:145);

and the C-terminal amidated forms thereof, wherein X is
25 Har, x is D-Har, lower case letters represent D-amino acids
and lines between C and c residues represent disulfide
linkages.

7. The compound of Claim 2, wherein one of said
30 disulfide bridges links C₄-C₁₇, and the other links C₈-C₁₃.

8. The compound of Claim 7 which is selected from the group consisting of:

5 R-G-G-C-R-L-Y-C-R
| | R
| | R
R-C-G-V-V-C-F (SEQ ID NO:6);

10 R-G-G-C-R-L-Y-C-R
| | R
| | R
R-C-G-V-I-C-F (SEQ ID NO:7);

15 R-G-G-C-G-L-Y-C-R
| | R
| | R
R-C-G-V-V-C-F (SEQ ID NO:8);

20 R-G-G-C-R-L-Y-C-R
| | G
| | W
R-C-G-V-F-C-I (SEQ ID NO:9);

25 R-G-G-C-R-L-Y-C-R
| | P
| | R
R-C-G-V-V-C-F (SEQ ID NO:10);

25 R-G-G-C-R-V-Y-C-R
| | R
| | R
C-G-I-V-C-F (SEQ ID NO:146);

25 K-G-G-C-R-I-Y-C-R
| | R
| | R
C-G-I-V-C-F (SEQ ID NO:147);

30 R-G-G-C-X-L-Y-C-X
| | R
| | R
R-C-G-C-I-V-C-F (SEQ ID NO:148);

	R-G-G-C-R-V-Y-C-R X R-C-G-V-V-C-F	(SEQ ID NO:149);
5	R-G-G-C-R-L-Y-C-R K R-C-G-V-V-C-W	(SEQ ID NO:150);
10	R-G-G-C-R-L-Y-C-R X R-C-A-V-V-C-Y	(SEQ ID NO:151);
	R-G-S-C-G-L-Y-C-R R R-C-G-V-V-C-W	(SEQ ID NO:152);
15	R-A-T-C-R-I-F-C-R R R-C-G-I-V-C-F	(SEQ ID NO:153);
20	R-G-G-C-K-V-Y-C-R X R-C-G-I-V-C-F	(SEQ ID NO:154);
	R-A-T-C-R-I-F-C-r R r-C-G-V-V-C-F	(SEQ ID NO:155);
25	R-G-G-C-K-V-Y-C-R X R-C-G-V-V-C-F	(SEQ ID NO:156);
30	r-g-g-c-r-l-y-c-r r r-c-g-v-v-c-f	(SEQ ID NO:157);

	r-g-g-c-r-l-y-c-r r c-g-v-i-c-f	(SEQ ID NO:158);
5	r-g-g-c-r-l-y-c-r r c-g-v-i-c-f	(SEQ ID NO:159);
10	r-g-g-c-r-l-y-c-r g r-c-g-v-f-c-i	(SEQ ID NO:160);
	R-G-G-C-L-R-Y-C-R P R-C-V-R-V-C-F	(SEQ ID NO:161);
15	R-G-V-C-L-R-Y-C-R G R-C-L-R-V-C-F	(SEQ ID NO:162);
20	R-R-G-V-C-L-R-Y-C-R G R-F-C-L-R-V-C-F	(SEQ ID NO:163);
	R-W-R-V-C-L-R-Y-C-R G R-L-C-L-R-V-C-F	(SEQ ID NO:164);
25	R-G-W-R-V-C-L-K-Y-C-R G R-L-C-L-K-V-C-F	(SEQ ID NO:165);
30	R-G-G-R-V-C-L-R-Y-C-R G R-L-C-L-R-V-C-F	(SEQ ID NO:166);

	R-G-G-C-L-R-Y-C-R P R-C-C-V-R-C-F	(SEQ ID NO:167);
5	R-G-G-C-R-L-Y-C-R R R-C-G-V-V-C-F	(SEQ ID NO:168);
10	R-G-V-C-L-R-Y-C-R G R-C-L-R-V-C-F	(SEQ ID NO:169);
	R-G-R-V-C-L-R-Y-C-R G R-F-C-L-R-V-C-F	(SEQ ID NO:170);
15	R-W-R-V-C-L-R-Y-C-R G R-L-C-L-R-V-C-F	(SEQ ID NO:171);
20	R-G-W-R-V-C-L-K-Y-C-R G R-L-C-L-K-V-C-F	(SEQ ID NO:172);
	R-G-G-R-V-C-L-R-Y-C-R G R-L-C-L-R-V-C-F	(SEQ ID NO:173);
25	R-G-G-C-R-L-Y-C-R R C-G-V-V-C-F	(SEQ ID NO:174)

and the C-terminal amidated forms thereof, wherein X is
Har, x is D-Har, lower case letters represent D-amino acids
30

and lines between C or c residues represent disulfide linkages.

9. The compound of Claim 1 which comprises one
5 disulfide bridge.

10. The compound of Claim 9 in which said disulfide bridge links C₄-C₁₇.

10
11. The compound of Claim 10 which is selected from the group consisting of:

15 R-G-G-C-L-R-Y-A-V
|
| P
R-C-V-R-V-A-F R (SEQ ID NO:175) ;

R-G-G-C-L-R-Y-T-K
|
| P
R-C-V-R-V-T-F K (SEQ ID NO:176) ;

20 R-G-G-C-L-R-Y-A-V
|
| G
R-C-V-R-V-A-F R (SEQ ID NO:177) ;

R-G-G-C-X-L-Y-A-X
|
| R
R-C-G-V-V-S-F R (SEQ ID NO:178) ;

25 R-G-G-C-L-R-Y-A-R
|
| Z
R-C-V-R-V-A-F R (SEQ ID NO:179) ;

R-G-F-C-L-R-Y-T-V
|
| P
R-V-C-F-R-V-T-F R (SEQ ID NO:180) ;
30

R-G-F-C-L-R-Y-K-V
 |
 | G
 | R
 R-V-C-F-R-V-K-F
 R-G-F-C-L-R-Y-Z-V
 |
 | G
 | R
 R-V-C-F-R-V-Z-F
 R-G-G-C-L-R-Y-A-R
 |
 | Z
 | R
 R-C-V-R-V-A-F
 R-G-G-C-L-R-Y-A-V
 |
 | G
 | R
 R-C-V-R-V-A-F

and the C-terminal amidated forms thereof, wherein X is
 Har, Z is MeGly and lines between C residues represent
 15 disulfide linkages.

12. The compound of Claim 9 in which said disulfide
 bridge links C₅-C₁₆.

20 13. The compound of Claim 12 which is selected from the
 group consisting of:

R-G-G-R-C-L-Y-A-R
 |
 | R
 | R
 R-G-C-V-V-A-F
 R-G-G-R-C-L-Y-A-R
 |
 | R
 | R
 C-V-I-S-F
 R-G-G-G-C-L-Y-S-R
 |
 | R
 | R
 R-G-C-V-V-A-F

R-G-G-R-C-L-Y-A-R
 |
 |
 C-V-V-G-F (SEQ ID NO:188) ;

5 K-G-G-R-C-L-Y-A-R
 |
 |
 C-V-V-I-F (SEQ ID NO:189) ;

R-G-G-X-C-L-Y-A-X
 |
 |
 R-G-C-V-V-S-F (SEQ ID NO:190) ;

10 R-G-G-R-C-L-Y-S-R
 |
 |
 R-G-C-S-V-A-W (SEQ ID NO:191) ;

15 R-G-G-R-C-L-Y-S-R
 |
 |
 R-G-C-I-V-S-Y (SEQ ID NO:192) ;

R-A-T-R-C-I-F-S-R
 |
 |
 R-G-C-V-V-S-F (SEQ ID NO:193) ;

20 R-G-G-K-C-V-Y-G-R
 |
 |
 R-G-C-V-V-S-F (SEQ ID NO:194) ;

R-A-T-R-C-I-F-G-r
 |
 |
 r-G-C-V-V-G-F (SEQ ID NO:195) ;

25 R-G-G-K-C-V-Y-L-R
 |
 |
 R-G-C-V-V-L-F (SEQ ID NO:196) ;

R-G-G-R-C-V-F-L-R
 |
 |
 R-G-C-V-V-G-I (SEQ ID NO:197) ;

30

and the C-terminal amidated forms thereof, wherein X is Har, x is D-Har, lower case letters represent D-amino acids and lines between C residues represent disulfide linkages.

5 14. The compound of Claim 9 in which the disulfide bridge links C₈ and C₁₃.

15. The compound of Claim 1 which is in the linear form.

10 16. The compound of Claim 1 in which at least one of A₁, A₂ or A₃ is not present.

17. The compound of Claim 1 in which A₁, A₂ and A₃ are not 15 present.

18. The compound of Claim 1 in which at least one of A₁, A₂ or A₃ is a hydrophobic amino acid.

20 19. The compound of Claim 1 in which each of C₅ and C₁₆ is independently selected from the group consisting of cysteine, homocysteine, penicillamine, I, V, L, NLe, W, Y, F, A, S, G and T.

25 20. The compound of Claim 1 in which each of C₄ and C₁₇ is independently selected from the group consisting of cysteine, homocysteine, penicillamine, I, V, L, NLe, W, Y, F, A, S, G and T.

30

21. The compound of Claim 1 in which each of A₇ and A₁₄ is independently selected from the group consisting of I, V, L, NLe, W, Y, F, A, S, G and T.

5 22. The compound of Claim 1 in which one of A₉ or A₁₂ is R, K, Har, Orn or H and the other is I, V, L, NLe, W, Y, F, A, S, G or T.

23. The compound of Claim 1 in which all amino acids
10 are in the D-configuration.

24. The compound of Claim 1 in which A₇ and A₁₄ are each independently a hydrophobic amino acid.

15 25. The compound of Claim 1 in which A₉ or A₁₂ is a hydrophobic amino acid or a small amino acid.

26. The compound of Claim 1 in which A₁₀ and A₁₁ are each independently selected from the group consisting of proline,
20 a basic amino acid, a hydrophobic amino acid and a small amino acid.

27. The compound of Claim 1 in which each of C₈ and C₁₃ is independently cysteine, homocysteine or penicillamine.

25

28. The compound of Claim 1 in which A₉-A₁₀-A₁₁-A₁₂ is selected from the group consisting of: R-R-R-F, R-G-W-I, R-P-R-F, X-R-R-F, R-X-RF, R-K-K-W, R-X-R-Y, R-R-K-W, r-R-R-F, R-x-R-F, R-G-R-F, C-R-G-R, Y-C-G-R, V-P-R-F, K-P-K-F,

30

V-G-R-F, R-P-R-I and R-Z-R-F, where X is Har, x is D-Har, Z is MeGly and r is D-Arg.

29. The compound of Claim 1 which is in the linear or
5 disulfide-bridged form and which is selected from the group
consisting of:

	RGGRCLYCRRLFCVVCGR	(SEQ ID NO:11);
	RGGCRLYCRRLFCVVGCR	(SEQ ID NO:12);
	RGGRCLYCRRLFCIVCG	(SEQ ID NO:13);
10	RGGCRLYCRRLFCIVGC	(SEQ ID NO:14);
	RGGGCLYCRRLFCVVCGR	(SEQ ID NO:15);
	RGGCGLYCRRLFCVVGCR	(SEQ ID NO:16);
	RGGRCLYCRGWICFVCGR	(SEQ ID NO:17);
	RGGCRLYCRGWICFVGCR	(SEQ ID NO:18);
15	RGGRCLYCRPRFCVVCGR	(SEQ ID NO:19);
	RGGCRLYCRPRFCVVGCR	(SEQ ID NO:20);
	RGGRCVYCRRLFCVVCG	(SEQ ID NO:21);
	RGGCRVYCRRLFCVIGC	(SEQ ID NO:22);
	KGGRCLYCRRLFCVVCG	(SEQ ID NO:23);
20	KGGCRIYCRRLFCVIGC	(SEQ ID NO:24);
	RGGXCLYCRRLFCVVC	(SEQ ID NO:25);
	RGGCXLYCRRLFCVIC	(SEQ ID NO:26);
	RGGXCLYCXRRFCVVCGR	(SEQ ID NO:27);
	RGGCXLYCXRRFCVIGCR	(SEQ ID NO:28);
25	RGGRCVYCRXRFCCVVCGR	(SEQ ID NO:29);
	RGGCRVYCRXRFCCVVGCR	(SEQ ID NO:30);
	RGGRCLYCRKKWCVVCGR	(SEQ ID NO:31);
	RGGCRLYCRKKWCVVGCR	(SEQ ID NO:32);
	RGGRCLYCRXRYCVVCGR	(SEQ ID NO:33);
30	RGGCRLYCRXRYCVVACR	(SEQ ID NO:34);

DRAFT - 2023-07-10

	RGSGCLYCRRKWCVVCGR	(SEQ ID NO:35);
	RGSCGLYCRRKWCVVGCR	(SEQ ID NO:36);
	RATRCIFCRRRFCVVCGR	(SEQ ID NO:37);
	RATCRIFCRRRFCVIGCR	(SEQ ID NO:38);
5	RGGKCVYCRXRFCVVCGR	(SEQ ID NO:39);
	RGGCKVYCRXRFCVIGCR	(SEQ ID NO:40);
	RATRCIFCrrRFCVVCGr	(SEQ ID NO:41);
	RATCRIFCrRRRFCVVGCr	(SEQ ID NO:42);
	RGGKCVYCRxRFCVVCGR	(SEQ ID NO:43);
10	RGGCKVYCRxRFCVVGCR	(SEQ ID NO:44);
	rggrclysrrrfcvvcgr	(SEQ ID NO:45);
	rggcrlclysrrrfcvvgcr	(SEQ ID NO:46);
	rggrclysrrrfcivcg	(SEQ ID NO:47);
	rggcrlclysrrrfcivgc	(SEQ ID NO:48);
15	rgggclysrrrfcvvcgr	(SEQ ID NO:49);
	rggcglycrrrfcvvgcr	(SEQ ID NO:50);
	rggrclysrgwicfvvcgr	(SEQ ID NO:51);
	rggcrlcrysrgwicfvvcgr	(SEQ ID NO:52);
	RGGCLRYCRPRFCVRLVCR	(SEQ ID NO:53);
20	RGGCRLYCRRRFCVVGCR	(SEQ ID NO:54);
	RGVCLRYCRGRFCVRLCR	(SEQ ID NO:55);
	RGRVCLRYCRGRFCVRLCFR	(SEQ ID NO:56);
	RWRVCLRYCRGRFCVRLCLR	(SEQ ID NO:57);
	RGWRVCLKYCRGRFCVKLCLR	(SEQ ID NO:58);
25	RGGRVCLRYCRGKFCVRLCLR	(SEQ ID NO:59);
	RGGRCLYARRRFAVVCGR	(SEQ ID NO:60);
	RGGRCLYARRRFsIVC	(SEQ ID NO:61);
	RGGGCLYSRRRFAVVCGR	(SEQ ID NO:62);
	RGGRCLYARRRFGVVC	(SEQ ID NO:63);
30	KGGRCLYVRRRFIVVC	(SEQ ID NO:64);

	RGGXCLYARRRFVGCV	(SEQ ID NO:65) ;
	RGGXCLYAXRRFSVVCR	(SEQ ID NO:66) ;
	RGGCXLYAXRRFSVVGCR	(SEQ ID NO:67) ;
	RGGRCVYVRXRFLVCVGR	(SEQ ID NO:68) ;
5	RGGRCLYSRKKAWSVSCGR	(SEQ ID NO:69) ;
	RGGRCLYSRXRYSVICGR	(SEQ ID NO:70) ;
	RGSGCIYCRKKGWVVGCR	(SEQ ID NO:71) ;
	RATRCIFSRRFSVVCGR	(SEQ ID NO:72) ;
	RGGKCVYGRXRFVVCGR	(SEQ ID NO:73) ;
10	RATRCIFGRRRFGVVCGR	(SEQ ID NO:74) ;
	RGGKCVYLRxRFLVVCGR	(SEQ ID NO:75) ;
	RGGRCVFLRPRIGVVCGR	(SEQ ID NO:76) ;
	RGGCLRYAVPRFAVRVCR	(SEQ ID NO:77) ;
	RGGCLRYTKPKFTVRVCR	(SEQ ID NO:78) ;
15	RGGCLRYAVGRFAVRVCR	(SEQ ID NO:79) ;
	RGGCLRYARZRFAVRVCR	(SEQ ID NO:80) ;
	RGFCLRYTVPRFTVRFCVR	(SEQ ID NO:81) ;
	RGFCLRYKVGRFKVRCVR	(SEQ ID NO:82) ;
	RGFCLRYZVGRFZVRFCVR	(SEQ ID NO:83) ;
20	RGGCLRYARZRFAVRVCR	(SEQ ID NO:84) ;
	RGGCLRYAVGRFAVRVCR	(SEQ ID NO:85) ;
	RGGRCLYCRRRFCVVGCR	(SEQ ID NO:86) ;
	RGGCRLYCRRRFCVVCGR	(SEQ ID NO:87) ;
	RGGRCLYCRRRFCVCGR	(SEQ ID NO:88) ;
25	RGGCRLYCRRRFCVCGR	(SEQ ID NO:89) ;
	RGGRLCYCRRRFCVVCGR	(SEQ ID NO:90) ;
	RGGRLCYCRRRFCVVGCR	(SEQ ID NO:91) ;
	RGGCRLYCRRRFCVVGCR	(SEQ ID NO:92) ;
	RGGRCLYCRRRFCVVGCR	(SEQ ID NO:93) ;
30	RGGCRLYCRRRFCVVGCR	(SEQ ID NO:94) ;

RGGRCLYCR ^{RR} FCVCVG	(SEQ ID NO:95);
RGGCRLYCR ^{RR} FCVCVG	(SEQ ID NO:96);
RGGRLCYCR ^{RR} FCVVCG	(SEQ ID NO:97);
RGGRLCYCR ^{RR} FCVVGC	(SEQ ID NO:98);
RGGGCLYCR ^{RR} FCVVGCR	(SEQ ID NO:99);
RGGGCLYCR ^{RR} FCVCVGR	(SEQ ID NO:100);
RGGCGLYCR ^{RR} FCVCVGR	(SEQ ID NO:101);
RGGGLCYCR ^{RR} FCVVCGR	(SEQ ID NO:102);
RGGGLCYCR ^{RR} FCVVGCR	(SEQ ID NO:103);

10 and the C-terminal amidated and N-terminal acylated forms thereof, wherein X is Har, x is D-Har, Z is MeGly and lower case letters represent D-amino acids.

30. A pharmaceutical composition comprising a compound
15 according to Claim 1 and a pharmaceutically acceptable
excipient.

31. A method of inhibiting the growth of a microbe or
the replication of a virus which comprises the step of
20 contacting said virus or said microbe with an amount of a
compound according to Claim 1 effective to inhibit said
growth or said replication.

32. The method of Claim 31 in which the microbe is a
25 bacteria.

33. The method of Claim 32 in which the bacteria is selected from the group consisting of *E. coli*, *L. monocytogenes*, *B. subtilis*, *S. typhimurium*, *S. aureus* and *P. aeruginosa*.

34. The method of Claim 31 in which the microbe or virus is a sexually-transmitted microbe or virus.

35. The method of Claim 34 in which the sexually-
5 transmitted microbe or virus is selected from the group consisting of HIV-1, C. trachomatis, T. pallidum, N. gonorrhoeae, T. vaginalis, HSV-1, HSV-2, H. ducreyi and human papilloma virus.

10 36. The method of Claim 31 in which the microbe or virus is HIV.

37. The method of Claim 31 in which the microbe or virus is methicillin-resistant S. aureus (MRSA) or
15 vancomycin-resistant E. faecalis (VREF).

38. A method to inactivate the endotoxin of gram-negative bacteria, which method comprises contacting said endotoxin with an amount of a compound according to Claim 1
20 effective to inactivate said endotoxin.

39. A method to treat or prevent a microbial or viral infection in a subject, which method comprises administering to a subject in need of such treatment an amount of a
25 compound according to Claim 1 effective to ameliorate said infection in the subject.

40. The method of Claim 39 in which the infection is a bacterial infection.

30

41. The method of Claim 40 in which the bacteria is selected from the group consisting of E. Coli, L. monocytogenes, B. subtilis, S. typhimurium, S. aureus and P. aeruginosa.

5

42. The method of Claim 39 in which the infection is caused by a sexually-transmitted pathogen.

43. The method of Claim 42 in which the sexually-
10 transmitted pathogen is selected from the group consisting of HIV-1, C. trachomatis, T. pallidum, N. gonorrhoeae, T. vaginalis, HSV-1, HSV-2, H. ducreyi and human papilloma virus.

15 44. The method of Claim 39 in which the infection is an HIV infection.

45. The method of Claim 39 in which the infection is a methicillin-resistant S. aureus (MRSA) or vancomycin-
20 resistant E. faecalis (VREF) infection.

46. The method of Claim 39 in which the compound is administered topically.

25 47. The method of Claim 39 in which the compound is administered prophylactically.

30